St. Jude Medical completed its acquisition of Thoratec on Oct. 8, expanding its heart failure business and adding products such as the HeartMate II left ventricular assist device.
Thoratec shareholders will receive $63.50 in cash for each Thoratec share they owned. St. Jude Medical expects the deal to be accretive to adjusted earnings per share next year.
More than 21,000 patients have been implanted with the HeartMate II device, which is FDA-approved for bridge-to-transplantation and destination therapy. More than 365 medical centers in the U.S., Europe, Japan, Asia Pacific, Australia, Canada and Latin America implant the devices.
In September, Thoratec issued an urgent medical device correction letter alerting hospitals to monitor the expiration date of the backup battery contained in the HeartMate II device.
Thoratec also has an investigational chronic mechanical circulatory support device called the HeartMate 3 that is intended for advanced heart failure patients. A clinical trial is underway to evaluate the device for destination therapy and bridge-to-transplantation. The study, which is currently enrolling patients, compares the HeartMate II and HeartMate 3 devices.
Thoratec expects the HeartMate 3 device to be approved in Europe by the end of 2015.